About
Global generic/biosimilar company (spun out of Novartis 2023). Acquired the Cimerli (ranibizumab biosimilar) franchise for $170m cash.
HQ: Basel, Switzerland
Funding
Public (SIX/NYSE: SDZ)
—Company profile
Generic and biosimilar maker — bought the Cimerli ophthalmology franchise for $170m.
Global generic/biosimilar company (spun out of Novartis 2023). Acquired the Cimerli (ranibizumab biosimilar) franchise for $170m cash.
HQ: Basel, Switzerland